[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
    "summary": "Health care stocks rose late Monday afternoon with the NYSE Health Care Index up 0.4% and the Health",
    "url": "https://finnhub.io/api/news?id=904ce749689e3d6f87f1afa1da608abadbd5320b37798fa02fc43b0fcd295595",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751313385,
      "headline": "Sector Update: Health Care Stocks Higher Late Afternoon",
      "id": 135676896,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Monday afternoon with the NYSE Health Care Index up 0.4% and the Health",
      "url": "https://finnhub.io/api/news?id=904ce749689e3d6f87f1afa1da608abadbd5320b37798fa02fc43b0fcd295595"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Monday Afternoon",
    "summary": "Health care stocks rose Monday afternoon with the NYSE Health Care Index climbing 0.2% and the Healt",
    "url": "https://finnhub.io/api/news?id=689102be9f16142682ef3874bdaf9485ab2e814095819d3a9faf2330bf1cccff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751305744,
      "headline": "Sector Update: Health Care Stocks Advance Monday Afternoon",
      "id": 135671101,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Health care stocks rose Monday afternoon with the NYSE Health Care Index climbing 0.2% and the Healt",
      "url": "https://finnhub.io/api/news?id=689102be9f16142682ef3874bdaf9485ab2e814095819d3a9faf2330bf1cccff"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. entered into an definitive agreement to acquire Capstan Therapeutics, Inc. for $2.1 billion.",
    "summary": "AbbVie Inc. entered into an definitive agreement to acquire Capstan Therapeutics, Inc. for $2.1 billion on June 30, 2025. AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class...",
    "url": "https://finnhub.io/api/news?id=edafd3be17e241c389a1fc96a5c5d24974384844f976eec6881d2bf26151d97f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751303584,
      "headline": "AbbVie Inc. entered into an definitive agreement to acquire Capstan Therapeutics, Inc. for $2.1 billion.",
      "id": 135675595,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie Inc. entered into an definitive agreement to acquire Capstan Therapeutics, Inc. for $2.1 billion on June 30, 2025. AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class...",
      "url": "https://finnhub.io/api/news?id=edafd3be17e241c389a1fc96a5c5d24974384844f976eec6881d2bf26151d97f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=24ee11cd3e3234c51997007f8f4fbeaf09e649e862a7bd2c7b41004f4804619c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751301060,
      "headline": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "id": 135689122,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=24ee11cd3e3234c51997007f8f4fbeaf09e649e862a7bd2c7b41004f4804619c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc.(NYSE: ABBV) dropped from Russell 1000 Value-Defensive Index",
    "summary": "AbbVie Inc. dropped from Russell 1000 Value-Defensive Index...",
    "url": "https://finnhub.io/api/news?id=dcde8fe69687fd2554f0f8b120fbdbd9830d294effffe04ed09466186fd99280",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751300422,
      "headline": "AbbVie Inc.(NYSE: ABBV) dropped from Russell 1000 Value-Defensive Index",
      "id": 135674600,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie Inc. dropped from Russell 1000 Value-Defensive Index...",
      "url": "https://finnhub.io/api/news?id=dcde8fe69687fd2554f0f8b120fbdbd9830d294effffe04ed09466186fd99280"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Hewlett Packard, Juniper Settle Antitrust Suit With DOJ; Home Depot Unit Acquires GMS for $5.5 Billion",
    "summary": "All three major US stock indexes were up in late-morning trading Monday after Canada announced late",
    "url": "https://finnhub.io/api/news?id=e4cfa381cf82b99f0a852c2cc82ac52c026229316182b361b1003c05ef96bec3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751297858,
      "headline": "Top Midday Stories: Hewlett Packard, Juniper Settle Antitrust Suit With DOJ; Home Depot Unit Acquires GMS for $5.5 Billion",
      "id": 135663770,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were up in late-morning trading Monday after Canada announced late",
      "url": "https://finnhub.io/api/news?id=e4cfa381cf82b99f0a852c2cc82ac52c026229316182b361b1003c05ef96bec3"
    }
  },
  {
    "ts": null,
    "headline": "Stocks See Support as Signs of Trade Progress Boost Market Sentiment",
    "summary": "The S&P 500 Index ($SPX ) (SPY ) today is up +0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.40%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.38%. September E-mini S&P futures (ESU25 ) are up +0.27%, and September E-mini Nasdaq futures...",
    "url": "https://finnhub.io/api/news?id=9ab2f61b8204611f3da61139c7ba1a70abd25e74770215c53709d4e7f27414a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751292476,
      "headline": "Stocks See Support as Signs of Trade Progress Boost Market Sentiment",
      "id": 135661457,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The S&P 500 Index ($SPX ) (SPY ) today is up +0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.40%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.38%. September E-mini S&P futures (ESU25 ) are up +0.27%, and September E-mini Nasdaq futures...",
      "url": "https://finnhub.io/api/news?id=9ab2f61b8204611f3da61139c7ba1a70abd25e74770215c53709d4e7f27414a1"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion",
    "summary": "BUSINESS   AbbVie agreed to acquire Capstan Therapeutics, including its lead asset, for $2.1 billion in cash. The North Chicago, Ill., drugmaker’s planned acquisition includes CPTX2309, which is currently in Phase 1 and in development for the treatment of B cell-mediated autoimmune diseases.",
    "url": "https://finnhub.io/api/news?id=0551a3ab42df0f71c378171b689a1c5fb431a7a289c3a919cac1d8dbfcd71ff2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751288220,
      "headline": "AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion",
      "id": 135671439,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "BUSINESS   AbbVie agreed to acquire Capstan Therapeutics, including its lead asset, for $2.1 billion in cash. The North Chicago, Ill., drugmaker’s planned acquisition includes CPTX2309, which is currently in Phase 1 and in development for the treatment of B cell-mediated autoimmune diseases.",
      "url": "https://finnhub.io/api/news?id=0551a3ab42df0f71c378171b689a1c5fb431a7a289c3a919cac1d8dbfcd71ff2"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to buy Capstan for up to $2.1 billion in immunology push",
    "summary": "(Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments for autoimmune diseases.  The U.S. drugmaker has spent over $20 billion on acquisitions since 2023 as its flagship rheumatoid arthritis drug, Humira, lost patent protection.  Capstan develops CAR-T therapies, which use a patient's own immune cells, specifically T-cells, to fight diseases.",
    "url": "https://finnhub.io/api/news?id=1ae7614f475c00531f3dbe2acbf715de5078e4f06d6d3394596db612a35b334f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751287323,
      "headline": "AbbVie to buy Capstan for up to $2.1 billion in immunology push",
      "id": 135666209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "(Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments for autoimmune diseases.  The U.S. drugmaker has spent over $20 billion on acquisitions since 2023 as its flagship rheumatoid arthritis drug, Humira, lost patent protection.  Capstan develops CAR-T therapies, which use a patient's own immune cells, specifically T-cells, to fight diseases.",
      "url": "https://finnhub.io/api/news?id=1ae7614f475c00531f3dbe2acbf715de5078e4f06d6d3394596db612a35b334f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology",
    "summary": "AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. (\"Capstan\"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today announced a definitive agreement under which AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, currently in Phase 1, in development for the treatment of B cell-mediated autoimmune diseases. Additionally, AbbVie will acquire Capstan",
    "url": "https://finnhub.io/api/news?id=cb012327529093f44266a1d04619555baaa6ffe187b39305844534a91e61bac6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751286660,
      "headline": "AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology",
      "id": 135671441,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. (\"Capstan\"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today announced a definitive agreement under which AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, currently in Phase 1, in development for the treatment of B cell-mediated autoimmune diseases. Additionally, AbbVie will acquire Capstan",
      "url": "https://finnhub.io/api/news?id=cb012327529093f44266a1d04619555baaa6ffe187b39305844534a91e61bac6"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance",
    "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental premarket approval (sPMA) application for SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance. SKINVIVE by JUVÉDERM® is currently approved in the U.S. to improve skin smoothness of the cheeks in adults over the age of 21.",
    "url": "https://finnhub.io/api/news?id=b2c52faf0fb89f2a6e1094c7b214666235993fe61762ae8d0d555ba59e715dac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751286300,
      "headline": "U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance",
      "id": 135671442,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental premarket approval (sPMA) application for SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance. SKINVIVE by JUVÉDERM® is currently approved in the U.S. to improve skin smoothness of the cheeks in adults over the age of 21.",
      "url": "https://finnhub.io/api/news?id=b2c52faf0fb89f2a6e1094c7b214666235993fe61762ae8d0d555ba59e715dac"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to buy CAR-T developer Capstan in deal worth up to $2.1B",
    "summary": "The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.",
    "url": "https://finnhub.io/api/news?id=ac6f75fe04531bfc1ec1b845e46907a89ae246c9b31a8c2dad6df602ec63572f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751284800,
      "headline": "AbbVie to buy CAR-T developer Capstan in deal worth up to $2.1B",
      "id": 135671444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.",
      "url": "https://finnhub.io/api/news?id=ac6f75fe04531bfc1ec1b845e46907a89ae246c9b31a8c2dad6df602ec63572f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Host Second-Quarter 2025 Earnings Conference Call",
    "summary": "AbbVie (NYSE: ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.",
    "url": "https://finnhub.io/api/news?id=f219b5f858a775cdf82784371a28e5ef0b62ccf286ec4a78518d853e560ccab1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751284800,
      "headline": "AbbVie to Host Second-Quarter 2025 Earnings Conference Call",
      "id": 135671443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) will announce its second-quarter 2025 financial results on Thursday, July 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.",
      "url": "https://finnhub.io/api/news?id=f219b5f858a775cdf82784371a28e5ef0b62ccf286ec4a78518d853e560ccab1"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: agreement to acquire Capstan",
    "summary": "AbbVie announces that it has entered into a definitive agreement to acquire Capstan Therapeutics, including CPTX2309, currently in Phase 1 development for the treatment of B-cell-mediated autoimmune...",
    "url": "https://finnhub.io/api/news?id=24320c1b8a01f79165c03c5b5ccdc8813476e17bbe241ea92931e261a144a8b1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751278547,
      "headline": "AbbVie: agreement to acquire Capstan",
      "id": 135653028,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie announces that it has entered into a definitive agreement to acquire Capstan Therapeutics, including CPTX2309, currently in Phase 1 development for the treatment of B-cell-mediated autoimmune...",
      "url": "https://finnhub.io/api/news?id=24320c1b8a01f79165c03c5b5ccdc8813476e17bbe241ea92931e261a144a8b1"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash",
    "summary": "By Denny Jacob AbbVie agreed to acquire Capstan Therapeutics, including its lead asset, for $2.1 billion in cash. The North Chicago, Ill., drugmaker's planned acquisition includes CPTX2309,...",
    "url": "https://finnhub.io/api/news?id=0a35ba4cf5b7710384c55d2ed2e356065a4c769a772fbea065be7d441ff29815",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751274191,
      "headline": "AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash",
      "id": 135651771,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Denny Jacob AbbVie agreed to acquire Capstan Therapeutics, including its lead asset, for $2.1 billion in cash. The North Chicago, Ill., drugmaker's planned acquisition includes CPTX2309,...",
      "url": "https://finnhub.io/api/news?id=0a35ba4cf5b7710384c55d2ed2e356065a4c769a772fbea065be7d441ff29815"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to buy Capstan Therapeutics for up to $2.1 billion",
    "summary": "June 30 - U.S. drugmaker AbbVie said on Monday it willacquire cell therapy developer Capstan Therapeutics in a cashdeal worth up to $2.1 billion. Capstan develops CAR-T...",
    "url": "https://finnhub.io/api/news?id=1fb5a2894489f8e461bb9d5051917f7e2899c6398d9f0f243d1050b1c7ed736d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751273536,
      "headline": "AbbVie to buy Capstan Therapeutics for up to $2.1 billion",
      "id": 135651576,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "June 30 - U.S. drugmaker AbbVie said on Monday it willacquire cell therapy developer Capstan Therapeutics in a cashdeal worth up to $2.1 billion. Capstan develops CAR-T...",
      "url": "https://finnhub.io/api/news?id=1fb5a2894489f8e461bb9d5051917f7e2899c6398d9f0f243d1050b1c7ed736d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc.(NYSE: ABBV) dropped from Russell 3000E Value Index",
    "summary": "AbbVie Inc. dropped from Russell 3000E Value Index...",
    "url": "https://finnhub.io/api/news?id=c389dce332f3359ca6dae0521df9674ded27610bc8cbc321b7fd9c16828357a0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751272226,
      "headline": "AbbVie Inc.(NYSE: ABBV) dropped from Russell 3000E Value Index",
      "id": 135651151,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie Inc. dropped from Russell 3000E Value Index...",
      "url": "https://finnhub.io/api/news?id=c389dce332f3359ca6dae0521df9674ded27610bc8cbc321b7fd9c16828357a0"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc.(NYSE: ABBV) dropped from Russell Top 200 Value Index",
    "summary": "AbbVie Inc. dropped from Russell Top 200 Value Index...",
    "url": "https://finnhub.io/api/news?id=302e9c47d8f16e172d884655b7a27c081f9bc7d87d4381d4bc77cc72de98fdc4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751271328,
      "headline": "AbbVie Inc.(NYSE: ABBV) dropped from Russell Top 200 Value Index",
      "id": 135650910,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie Inc. dropped from Russell Top 200 Value Index...",
      "url": "https://finnhub.io/api/news?id=302e9c47d8f16e172d884655b7a27c081f9bc7d87d4381d4bc77cc72de98fdc4"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc.(NYSE: ABBV) dropped from Russell 1000 Growth-Defensive Index",
    "summary": "AbbVie Inc. dropped from Russell 1000 Growth-Defensive Index...",
    "url": "https://finnhub.io/api/news?id=795b49f696be16af05f2ba787b61291f1a9ea76636e531201df1208223a9e3d7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751269744,
      "headline": "AbbVie Inc.(NYSE: ABBV) dropped from Russell 1000 Growth-Defensive Index",
      "id": 135650417,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie Inc. dropped from Russell 1000 Growth-Defensive Index...",
      "url": "https://finnhub.io/api/news?id=795b49f696be16af05f2ba787b61291f1a9ea76636e531201df1208223a9e3d7"
    }
  },
  {
    "ts": null,
    "headline": "This Changes Everything: One Of The Most Important Shifts For Dividend Investors",
    "summary": "Inflation isn't just back, it's becoming policy. Read why I'm sharpening my focus on pricing power, hard assets, and income that's built for this new reality.",
    "url": "https://finnhub.io/api/news?id=6717d8a1842f24e7cdc6fd6ac54bb5693c647a1fb7d3426c790987abbb7963d8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751268600,
      "headline": "This Changes Everything: One Of The Most Important Shifts For Dividend Investors",
      "id": 135650270,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2171101396/image_2171101396.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Inflation isn't just back, it's becoming policy. Read why I'm sharpening my focus on pricing power, hard assets, and income that's built for this new reality.",
      "url": "https://finnhub.io/api/news?id=6717d8a1842f24e7cdc6fd6ac54bb5693c647a1fb7d3426c790987abbb7963d8"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc.(NYSE: ABBV) dropped from Russell 1000 Value Index",
    "summary": "AbbVie Inc. dropped from Russell 1000 Value Index...",
    "url": "https://finnhub.io/api/news?id=f7efab7ab23cd3145b024e5277fb07bd73b0a8c08ff8ef10685cabb1b4213aa9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751258879,
      "headline": "AbbVie Inc.(NYSE: ABBV) dropped from Russell 1000 Value Index",
      "id": 135645695,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie Inc. dropped from Russell 1000 Value Index...",
      "url": "https://finnhub.io/api/news?id=f7efab7ab23cd3145b024e5277fb07bd73b0a8c08ff8ef10685cabb1b4213aa9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc.(NYSE: ABBV) dropped from Russell 1000 Defensive Index",
    "summary": "AbbVie Inc. dropped from Russell 1000 Defensive Index...",
    "url": "https://finnhub.io/api/news?id=d87e467780f256b9f64c10ca9221c89d59f1f4f84f65b93379c83507603de72f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751258768,
      "headline": "AbbVie Inc.(NYSE: ABBV) dropped from Russell 1000 Defensive Index",
      "id": 135645626,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie Inc. dropped from Russell 1000 Defensive Index...",
      "url": "https://finnhub.io/api/news?id=d87e467780f256b9f64c10ca9221c89d59f1f4f84f65b93379c83507603de72f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc.(NYSE: ABBV) dropped from Russell 3000 Value Index",
    "summary": "AbbVie Inc. dropped from Russell 3000 Value Index...",
    "url": "https://finnhub.io/api/news?id=71bf9c8b61aa410921ed1a8656c6a0c62a27ba8eb144485cda5590d9ddd6ae0e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751253043,
      "headline": "AbbVie Inc.(NYSE: ABBV) dropped from Russell 3000 Value Index",
      "id": 135641868,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie Inc. dropped from Russell 3000 Value Index...",
      "url": "https://finnhub.io/api/news?id=71bf9c8b61aa410921ed1a8656c6a0c62a27ba8eb144485cda5590d9ddd6ae0e"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories: FreeStyle Libre CGMs And EPD Business Driving Positive Momentum",
    "summary": "Abbott Laboratories: FreeStyle Libre CGMs And EPD Business Driving Positive Momentum",
    "url": "https://finnhub.io/api/news?id=86da78f5d0220b36cb802edf80f1f2a047f41632cadb8ad5bc127fc2c5266143",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751249970,
      "headline": "Abbott Laboratories: FreeStyle Libre CGMs And EPD Business Driving Positive Momentum",
      "id": 135639210,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=86da78f5d0220b36cb802edf80f1f2a047f41632cadb8ad5bc127fc2c5266143"
    }
  }
]